Searched for
DIVIS LABORATORIES STOCKS
Reliance Industries among 6 largecap stocks showing bullish RSI upswingSix largecap stocks featured in the RSI Trending Up scan on June 16, indicating improving price momentum across select counters. The signal...- Sunil Singhania-backed Abakkus Small Cap Fund adds 3 new stocks, increases stake in HDFC Bank, SBI and 49 othersSunil Singhania's Abakkus Small Cap Fund added three new stocks in May, including Tanla Platforms and Intellect Design Arena. The fund also...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- More women CXOs join India’s million-dollar pay club as domestic firms lead compensation growthNine women now earn over one million dollars annually as C-suite executives. Domestic companies are leading this rise, reflecting a focus o...
- For both the compulsive trader and careful investor: 25 stocks to watch if risk appetite returns; some with upside potential, some notIf the price of crude oil softens, Indian equities may again see a risk-on phase. Tariff concerns are no longer the central issue; the larg...
- Divi's Laboratories Q4 Results: Cons PAT grows 13% YoY to Rs 751 crore, revenue up 10%; Rs 30 per share dividend announcedDivi's Laboratories Q4 Results: Divi's Laboratories announced strong financial results for the March quarter. Net profit rose 13% to Rs 751...
- Mankind, other pharma stocks rally up to 7%; Nifty Pharma scales fresh peak. What lies ahead?Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...
- Pharma, NBFCs see fresh mutual fund buying in AprilIndian fund managers focused on defensive stocks in April. Pharmaceuticals saw increased investment due to opportunities like the semagluti...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Buy Divi's Laboratories, target price Rs 3742: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 98115.86 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3762: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 99034.38 Crore) operating in Pharmace...
- Divi's Labs Q1 Results: Profit nearly halves to Rs 356 crore on YoY basis, misses estimatesRevenue from operations during the first quarter dropped 21% to Rs 1,778 crore, compared with Rs 2,255 crore in the same quarter of last ye...
- Buy Divi's Laboratories, target price Rs 4130: Religare BrokingPromoters held 51.93 per cent stake in the company as of 30-Jun-2023, while FIIs owned 14.69 per cent, DIIs 21.03 per cent.
- Buy Divi's Laboratories, target price Rs 3576: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 94817.41 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3730: ICICI SecuritiesDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 94466.99 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 3579: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 93390.52 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 2912: ICICI DirectDivi's Laboratories, incorporated in the year 1990, is a Large Cap company (having a market cap of Rs 76314.25 Crore) operating in Pharmace...
- Buy Divi's Laboratories, target price Rs 4720: IIFLBuy Divi's Laboratories at a price target of Rs 4720 and a stoploss at Rs 4425 from entry point.
- Divi's Labs shares fall 9% post Sept quarter numbers; here's whyWe envisage near term pressures growin for Divi's Labs, with rising raw material prices, logistical issues and declining generics business,...
- India’s best-performing stock is seeing a wave of optimistic callsThe optimism is stemming from the company’s capacity-expansion plans and potential to win more business as India cuts its reliance on Chine...
Load More
